Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Freeline Therapeutics Holdings plc FRLN NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • GB • USD

SharesGrow Score
33/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Freeline Therapeutics Holdings plc (FRLN) is a Biotechnology company in the Healthcare sector, currently trading at $6.49. It has a SharesGrow Score of 31/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Net income is $89M (loss), growing at -29.3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $6M against $52M equity (Debt-to-Equity (D/E) ratio 0.11, conservative). Current ratio is 2.18 (strong liquidity). Debt-to-assets is 6.8%. Total assets: $87M.

Analyst outlook: 2 / 7 analysts rate FRLN as buy (29%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 20/100 (Fail), Income ?/100 (Fail).

FRLN SharesGrow Score Overview

41/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — FRLN

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
FRLN: +0%/yr revenue is, -29.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet FRLN: Debt-to-Equity (D/E) ratio 0.11 (conservative), Current ratio is 2.18 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
FRLN: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
20/100
Analyst outlook: 2 / 7 analysts rate FRLN as buy (29%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range2.11-8.745
Volume5.35K
Avg Volume (30D)28.14K
Market Cap$28.28M
Beta (1Y)0.66
Share Statistics
EPS (TTM)-22.52
Shares Outstanding$3.95M
IPO Date2020-08-07
Employees152
CEOMichael J. Parini
Financial Highlights & Ratios
Gross Profit$-1.74M
EBITDA$-97.17M
Net Income$-88.97M
Operating Income$-98.45M
Total Cash$47.28M
Total Debt$5.92M
Net Debt$-41.36M
Total Assets$86.64M
Price / Earnings (P/E)-0.3
Analyst Forecast
Rating ConsensusHold
Analysts Covering7
Buy 29% Hold 71% Sell 0%
Company Info
CountryGB
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS35655L1070

Price Chart

Track all markets on TradingView
FRLN
Freeline Therapeutics Holdings plc ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
2.11 52WK RANGE 8.75

People Also View

VECT
VECT
VectivBio Holding AG
$16.87
+0.12%
 IMMX
IMMX
Immix Biopharma, Inc.
$9.85
+1.65%
 SONN
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
-59.35%
 AVRO
AVRO
AVROBIO, Inc.
$1.40
-1.41%
 ZVSA
ZVSA
ZyVersa Therapeutics, Inc.
$0.19
-8.57%
 CNSP
CNSP
CNS Pharmaceuticals, Inc.
$2.64
+5.18%
 HEPA
HEPA
Hepion Pharmaceuticals, Inc.
$0.05
+18.52%
 NAVB
NAVB
Navidea Biopharmaceuticals, Inc.
$0.00
0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message